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Exosomes are nano-sized vesicles released by numerous cell types that appear to have diverse beneﬁcial
effects on the injured heart. Studies using exosomes from stem cells or from the blood have indicated
that they are able to protect the heart both in models of acute ischaemia and reperfusion, and during
chronic ischaemia. In addition to decreasing initial infarct size, they are able to stimulate angiogenesis,
reduce ﬁbrosis and remodelling, alter immune cell function and improve long-term cardiac contractile
function. However, since the technology and techniques used for the study of exosomes is relatively
immature and continually evolving, there remain many important caveats to the interpretation of
studies. This review presents a critical analysis of the ﬁeld of exosomes and cardioprotection. We analyse
the effects of exosomes from all types of stem cells investigated to date, summarize the major effects
observed and their potential mechanism, and offer our perspective on the major outstanding issues.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The involvement of larger extracellular vesicles (EVs) such as
microparticles or microvesicles (MVs) in thrombosis has been un-
derstood for many years (Boulanger et al., 2017). MVs are also un-
derstood to be a potential source of biomarkers of pathology
(Jansen et al., 2017; Sluijter et al., 2017). More recently, interest has
turned to their smaller cousins, namely exosomes, as it has become
apparent that they have the ability to transmit signals including
protein and miRNA between cells (Valadi et al., 2007). It therefore
seems likely that exosomes are involved in normal physiological,
and potentially also pathological processes (Lawson et al., 2016).
Since blood contains enormous numbers of exosomes released by
platelets, endothelium, and other cell types, it is clearly of interest
to investigate their role in the cardiovascular system, and to
determine their contribution to cardiovascular diseases (Sluijter
et al., 2017; Lawson et al., 2016).
Cardiovascular disease is the major cause of death not only in
developed countries but world-wide (Hausenloy and Yellon, 2013).
A major cause of cardiovascular disease is damage to the vascula-
ture resulting in gradual build-up of atherosclerotic plaques that
can partially occlude the vessel. If this occurs in the heart, it canavidson), d.yellon@ucl.ac.uk
Ltd. This is an open access article u
n, S.M., Yellon, D.M., Exosom
am.2017.11.004result in the distal myocardium becoming ischaemic under situa-
tions of increased cardiac demand. In some circumstances, the
plaque can rupture, exposing the intravascular wall to the coag-
gulative components of the blood which rapidly cause thrombotic
occlusion of the artery, followed by ischaemia, with the develop-
ment of an acute myocardial infarction. If the clot is not quickly
removed by thrombolysis or percutaneous coronary intervention,
or is not bypassed surgically (CABG), then the ischaemic myocar-
diumwill die. Thus, it is crucial to reperfuse the vessel as quickly as
possible. However, it has been known for many years that reper-
fusion causes a degree of additional injury, referred to as “reper-
fusion injury” (Hausenloy and Yellon, 2013; Bell et al., 2016;
Hausenloy et al., 2017; Lecour et al., 2014). As the ﬁnal infarct size
in patients with acute myocardial infarction (AMI) predicts long-
term clinical outcome (Lonborg et al., 2013), it is envisaged that
the identiﬁcation of means of minimizing this injury will reduce
patient mortality and morbidity.
To this end, many interventions have been investigated with the
aim of reducing reperfusion injury. However, despite their success
in animal studies, few have shown efﬁcacy in patients (Bell et al.,
2016; Hausenloy et al., 2017; Lecour et al., 2014; Kloner et al.,
2017). One of the most potent methods of protecting the heart in
experimental models is to subject it to several brief (3e5 min)
periods of ischaemia prior to a longer period of injurious ischaemia
and reperfusion, a procedure called ischaemic preconditioning
(IPC) (Hausenloy and Yellon, 2013; Hausenloy et al., 2017; Lecour
et al., 2014). Although the efﬁcacy of IPC has been demonstratednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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infarction in the majority of cases that occur spontaneously (Yellon
et al., 1993). There is therefore great interest in the potential for
remote IPC (RIPC), in which the preconditioning stimulus can be
easily applied to a limb remote from the heart, up to the time that
the myocardium is reperfused (Hausenloy and Yellon, 2013; Bell
et al., 2016; Davidson et al., 2013; Sharma et al., 2015). RIPC is
highly effective and reproducible in animal studies (Bromage et al.,
2017), and numerous phase I clinical trials have suggested efﬁcacy
at preventing myocardial injury in the setting of an AMI (Heusch
and Rassaf, 2016), yet it remains to be validated in a larger clin-
ical trial (Hausenloy et al., 2015).
One alternative approach to protecting the heart against the
initial insult of IR injury, is to attempt to restore the lost myocar-
dium, or at least improve its function. Unfortunately, since
mammalian cardiomyocytes are terminally differentiated there is
extremely limited scope for the spontaneous recovery of myocar-
dium by cardiomyocyte proliferation. However, a great deal of
effort has been expended in attempting to regenerate myocardium
by injecting different types of stem cells (Madonna et al., 2016).
Unfortunately this approach has also been largely unsuccessful in
creating new myocardium, despite some encouraging effects being
observed with respect to the preservation of existing myocardium,
and improvements in cardiac contractile function (Madonna et al.,
2016). Since these beneﬁts were clearly not mediated by an in-
crease in cardiomyocyte number, attention has recently turned to
factors that may be released from the remaining stem cells, and
that maymediate this paracrine effect. In particular, exosomes have
been proposed as an important potential paracrine factor (Fig. 1)
(Davidson et al., 2017a; Yellon and Davidson, 2014).
Exosomes, like all EVs, are enclosed by a lipid bilayer membrane,
and contain components originating from their cell of origin. Exo-
somes are some of the smallest EVs, typically only 50e150 nm in
diameter (Fig. 2). This renders them difﬁcult to visualize using
standard light imaging techniques, since they are smaller than the
wavelength of light. Most isolation procedures are able to achieve a
relative concentration of exosomes, but these preparations usually
also contain a certain number of MVs and other EVs, due to their
overlapping size distributions (Fig. 2). In particular, exosomes’
similar size and/or density to different lipoprotein particles makes
them extremely challenging to isolate at high purity from blood. To
avoid interference from bovine exosomes, cultured cells may beFig. 1. Exosomes can potentially exert effects on the heart via multiple different pathways.
effects. 2) Resident cardiac stem cells may cause autotrophic stimulation of themselves or o
cell types directly. 4) Exosomes administered systemically interact with cells of the cardiov
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risk of contamination by lipoprotein particles remains (Shelke et al.,
2014). Alternatively, in some studies, cells are cultured for several
days in serum-free medium, although this also runs the risk of
artefactually altering the cells. Consequently, using current tech-
niques, it is challenging to ascribe particular functional effects
speciﬁcally to exosomes. For this reason, some studies refer to
“exosomal” preparations more conservatively as “small EVs” (sEVs).
Given this uncertainty, it is crucial to consider the method of EV
isolation used in each individual study, since this determines to a
large extent the type of EVs in the preparation. This issue, and the
effect of different isolation methods has been extensively reviewed
(Sluijter et al., 2017), and is also discussed in other articles in this
series.
Despite the above caveats, important clues have been obtained
to suggest that EVs do play a role in cardiovascular health and
disease (Lawson et al., 2016). Recent reviews have given an excel-
lent description of the role of EVs more broadly in cardiovascular
and metabolic disease (Boulanger et al., 2017; Lawson et al., 2016;
Sluijter et al., 2014). The aim of the present review is to critically
review the literature investigating exosomes, their ability to protect
the heart and restore its function after IR injury.2. Mesenchymal stem cell-derived exosomes
Mesenchymal stem cells (MSCs) have generated extensive in-
terest due to their multi-lineage differentiation potential and their
ability to be expanded in vitro (Madonna et al., 2016; Zomer et al.,
2015a). A further advantageous characteristic is that MSCs can be
obtained from different tissues, whether foetal, young or adult,
although it appears that those derived from younger source tissues
are the more potent (Madonna et al., 2016). Interestingly, MSCs also
appear to have immunosuppressive properties (De Miguel et al.,
2012), raising the possibility that EVs originating from MSCs
might be able to confer multiple beneﬁts, not just on the heart
directly but via effects on cells of the immune system.
Lai et al. were the ﬁrst to show that exosomes from MSCs are
cardioprotective acutely (Lai et al., 2010a). They used HPLC to purify
exosomes released by MSCs in culture and injected them into the
tail veins of mice undergoing 30 min myocardial ischaemia via
ligation of the coronary artery (Lai et al., 2010a). In injected mice,
infarct size was signiﬁcantly reduced 24 h later (Lai et al., 2010a),1) Exosomes produced from intramyocardially injected stem cells can exert paracrine
ther cell types in the heart. 3) Exosomes injected intramyocardially can affect different
ascular system, including endothelium, blood cells and the heart.
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Fig. 2. The major characteristics of the different classes of small EV. Representative vesicles are shown to indicate the relative sizes, and transmission electron micrographs
demonstrate the “cup-shaped” appearance of the vesicles after preparation. Size bars as indicated.
Fig. 3. Some of the major effects that have been reported of exosomes that are relevant
to the ischaemic heart, and the cell types that have been reported to be involved in the
effect. See text for details.
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Importantly, a dose-response study was performed and at least
4 mg/kg exosomes were required to observe signiﬁcant beneﬁt
(Arslan et al., 2013). Furthermore, the MSC exosomes also protected
the isolated, perfused heart, meaning that protection was inde-
pendent of circulating immune cells (Arslan et al., 2013). In the
hearts of treated animals, higher levels of ATP and NADH as well as
lower levels of oxidative stress were observed but it is difﬁcult to
knowwhether this is a primary effect or is secondary to the smaller
infarcts (Arslan et al., 2013). To obtain insight into the potential
mechanism of protection, the proteome of MSC exosomes was
studied and 730 proteins were identiﬁed (Kim et al., 2012)
including the proteasome complex responsible for degradation of
proteins in the cytosol (Lai et al., 2012). Since the proteasome
complex is quite large 30 nm  12 nm there is a risk that it can co-
elute with the smaller exosomes. Interestingly, however, exosomes
have long been known to contain polyubiquitinated proteins, sug-
gesting they share a relationship with protein degradation path-
ways (Eitan et al., 2016). The source of MSC cells used in the above
studies is somewhat unusual, in that they were derived from hu-
man ES cells by several rounds of in vitro passaging and selection
(Lai et al., 2010a). However, the origin of the MSCs does not appear
to affect their ability to protect the heart. MSCs isolated from hu-
man foetal limb, kidney and liver tissue were all equally effective at
producing exosomes that were protective in an in vivo mouse
model of myocardial IR injury (Lai et al., 2010b).
MSC exosomes have also been shown to be protective in amodel
of permanent coronary artery ligation, in which the myocardium is
subject to continuing ischaemia without reperfusion. In these ex-
periments, exosomes were isolated from human umbilical cord
MSCs by ultracentrifugation then intravenously administrated
immediately following ligation of the left anterior descending
(LAD) coronary artery in rats (Zhao et al., 2015). Four weeks later,
improvements in cardiac systolic function were noted as well as a
reduction in cardiac apoptosis and ﬁbrosis (Zhao et al., 2015). The
MSC exosomes also promoted tube formation and migration of an
endothelial cell line in vitro (Zhao et al., 2015). However, it must be
noted that the exosomes isolated in this study were atypicallyPlease cite this article in press as: Davidson, S.M., Yellon, D.M., Exosom
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(NTA), and their appearance by transmission electron microscopy
(TEM) is more reminiscent of spherical lipoprotein particles than
the typical “cup-shaped” collapsed vesicular structure of true
exosomes (Zhao et al., 2015). This may reﬂect the fact that theMSCs
were cultured using medium containing serum, which contains
high concentrations of lipoprotein particles that overlap with
exosome in diameter and readily co-purify with exosomes (Shelke
et al., 2014).
In addition to an acute effect in reducing infarct size noted
above, part of the improvement in long-term cardiac function could
be due to effects on cardiac remodelling and revascularizationes and cardioprotection e A critical analysis, Molecular Aspects of
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genesis via the secretion of numerous proteins that might inﬂuence
endothelial growth and vessel sprouting, including VEGF and He-
patocyte Growth Factor (HGF) (Zomer et al., 2015a). However, there
is evidence that exosomes and larger EVs also mediate part of this
proangiogenic mechanism (Todorova et al., 2017). For example,
Gong et al. isolated exosomes isolated from a cell line ofMSCs called
C3H10T1/2 using Exoquick and found that they stimulated endo-
thelial proliferation in vitro (Gong et al., 2017). Shabbir et al. isolated
exosomes from human bone-marrow-derived-MSCs (BM-MSCs)
using differential ultracentrifugation, after ﬁrst clearing the calf
serum used to culture the cells of exosomes (Shabbir et al., 2015).
The BM-MSC exosomes stimulated tube formation of endothelial
cells in vitro, as well as the proliferation andmigration of ﬁbroblasts
(Shabbir et al., 2015). Liang et al. isolated exosomes by ﬁltration and
ultracentrifugation from cultured human adipose-derived MSCs
(AD-MSCs) in serum-containing medium, and showed that they
stimulated endothelial tube formation both in vitro and in a
Matrigel plug in vivo (Liang et al., 2016). Finally, Hu et al. showed
that MSC exosomes were able to enhance microvessel density and
blood perfusion in an in vivo mouse model of hind limb ischaemia.
The exosomes were isolated from iPSC-derived MSCs by a process
of ultraﬁltration and density gradient puriﬁcation, andwere further
veriﬁed to stimulate endothelial migration, proliferation, and tube
formation in vitro (Hu et al., 2015).
In attempting to determine the mechanism by which MSC
exosomes stimulate angiogenesis, many studies have focussed on
their miRNA content. Liang et al. determined that miR-125a was
enriched in their AD-MSC exosomes, and proposed that by trans-
ferring this miRNA to endothelial cells they promote angiogenesis
by repressing DLL4 (Liang et al., 2016). Gong et al. detectedmultiple
pro-angiomiRs in their MSC-exosomes, and by using loss and gain
of function experiments found that miR-30b was important for the
stimulation of endothelial proliferation in vitro (Gong et al., 2017).
Integrated transcriptomic and proteomic analysis of the molecular
cargo of EVs from porcine AD-MSCs demonstrated that their miRNA
and mRNA cargo targeted and encoded transcription factors (TFs),
and the EVs were enriched for proteins that support extracellular
matrix remodelling, blood coagulation, inﬂammation, and angio-
genesis (Eirin et al., 2017). A possible caveat with this study is that
cells were reportedly cultured in medium containing platelet lysate
(Eirin et al., 2017), and platelets are known to be major sources of
EVs including both MVs and exosomes (Heijnen et al., 1999).
Overall, it seems the particular balance of pro-angiogenic miRNAs
that stimulate angiogenesis may depend on the source of MSCs, and
is quite likely to vary with the experimental model. Analysis of
miRNA in exosomes released by cultured cells can be challenging,
not only because of the low yield, but because of potential inter-
ference frommiRNA contained in serum or other additives added to
the cell culture (Tosar et al., 2017). If, on the other hand, serum is
omitted, theremay be quite severe effects on the growth and health
of the cells.
An additional possible beneﬁt of MSC exosomes on cardiac
function could be via direct effects on cardiac contractility. For
example, exposure of human engineered cardiac tissue to exo-
somes from humanMSCs increased expression of calcium-handling
genes such as SERCA2a and the L-type calcium channel, and
consequently improved contractility while protecting from poten-
tial pro-arrhythmic effects of heterocellular coupling in the engi-
neered tissue (Mayourian et al., 2017). Uptake of ﬂuorescently
labelled exosomes was shown using cardiomyocytes differentiated
in vitro from stem cells. Although suggestive of an effect on car-
diomyocytes, such stem cell-derived cardiomyocytes are at a rela-
tively immature stage, therefore these experiments do not provide
direct evidence that MSC exosomes can affect the contractility ofPlease cite this article in press as: Davidson, S.M., Yellon, D.M., Exosom
Medicine (2017), https://doi.org/10.1016/j.mam.2017.11.004mature cardiomyocytes in the adult heart.
Attempts have been made to genetically engineer MSC exo-
somes so that they deliver even greater cardiovascular beneﬁts.
MSCs overexpressing GATA-4 produced exosomes that were able to
reduce infarct size and improved cardiac function when injected
intramyocardially prior to coronary artery ligation (Yu et al., 2014).
Their enhanced ability to protect the heart was attributed to their
increased content of anti-apoptotic miRs, in particular miR-19a
which resulted in increased activity of the PI3K/Akt kinase
pathway (Yu et al., 2014). This pathway is well-established as being
central to the so-called “Reperfusion injury Salvage Kinase (RISK)”
cardioprotective signalling pathway (Hausenloy and Yellon, 2013;
Hausenloy et al., 2017). Exosomal uptake into primary rat
neonatal cardiomyocytes was visualized in vitro. Kang et al. over-
expressed CXCR4 in MSC cells, since this receptor for SDF-1a is
important in homing and targeting of stem cells (Bromage et al.,
2014; Ziff et al., 2017). Furthermore, activation of the CXCR4-SDF-
1a pathway can protect the heart from IR injury, and may be
important for the suppression of heart failure (Sluijter et al., 2017;
Davidson et al., 2013; Bromage et al., 2014; Ziff et al., 2017; Malik
et al., 2015). Exosomes released by MSC-CXCR4 cells were found
to signiﬁcantly upregulate levels of IGF-1a and pAkt in car-
diomyocytes, as well as enhancing VEGF expression and vessel
formation in vitro (Kang et al., 2015). Ma et al. engineered human
umbilical cord MSCs to overexpress Akt and found that the exo-
somes produced by these cells had a greater ability to stimulate
angiogenesis (Ma et al., 2017). After intravenous injection, cardiac
function was improved following coronary artery ligation in rats
(Ma et al., 2017). Interestingly, Akt itself was detected in these
exosomes, although the pro-angiogenic stimulation was attributed
to platelet-derived growth factor D (PDGF-D) that was also present
within them (Ma et al., 2017).
As mentioned, another characteristic of MSCs is their immu-
nosuppression (Fig. 3). It is therefore important to establish
whether MSC-derived exosomes have the same intriguing capacity.
A recent well-performed study used size-exclusion chromatog-
raphy to obtain highly puriﬁed EVs from cultured umbilical cord
MSCs (Monguio-Tortajada et al., 2017). Cryo electron microscopy
and protein markers clearly demonstrated the presence of exo-
somes without protein contamination, although a size estimate of
~170 nm by NTA suggests there may have also been larger vesicles
present. Interestingly, in the different fractions analysed, only the
EVs were able to greatly immunosuppress polyclonal T cell activa-
tion (Monguio-Tortajada et al., 2017). The EVs did not have any
effect on macrophage polarization or cytokine secretion (Monguio-
Tortajada et al., 2017). As the authors note, this illustrates the
importance of working with well puriﬁed EV preparations, since
the non-EV fraction induced the expression of CD163 and CD206
and some production of TNF-a by monocytes (Monguio-Tortajada
et al., 2017). Intriguingly, one of the means by which MSCs regu-
late immunomodulation involves the release of the lipid based
signalling molecule prostaglandin E2 (Prockop and Oh, 2012). As
lipids, it is perhaps not surprising that prostaglandins have been
found to be associatedwith the lipidmembrane of exosomes (Subra
et al., 2010). However, whether PGE2 is involved in the mechanism
of immunosuppression by MSC exosomes has not yet been
investigated.
Although the results described in this section suggest the
exciting possibility of being able to harvest exosomes from cultured
MSCs and obtainingmost if not all of their beneﬁts in the absence of
the potential risks associated with the injection of live cells,
excitement must be tempered by several important caveats. Firstly,
despite clear evidence for uptake of exosomes into immature car-
diomyocytes and cell lines, the extent to which exosomes are able
to enter and deliver contents such as miRNA to mature, adultes and cardioprotection e A critical analysis, Molecular Aspects of
Fig. 4. The different potential sources of exosomes discussed in this review. Although
each type of cell has certain unique characteristics, the exosomes they produce are
notable for the consistent array of effects they induce.
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this, and have concluded that, actually, there is relatively little
uptake of exosomes into primary cardiomyocytes (Vicencio et al.,
2015; Agarwal et al., 2017; Gray et al., 2015). The evidence for up-
take into cardiomyocytes in vivo is even more limited, being mostly
limited to the indirect demonstration of altered gene expression,
which may be attributable to the delivery of miRNAs, but could
equally be a secondary response to receptor activation by
exosomal-surface proteins. One alternative is that the exosomes act
on the endothelium, as these expert scavenging cells can certainly
take up all types of exosomes including MSC exosomes (Gong et al.,
2017; Shabbir et al., 2015; Liang et al., 2016; Hu et al., 2015).
Furthermore, in some experiments the exosomes may not even be
acting directly on the myocardium, but may be reprogramming
macrophages or monocytes that have engulfed them. This hy-
pothesis is being actively investigated as the potential method of
action of CPC exosomes (de Couto et al., 2015; de Couto et al., 2017;
Kanazawa et al., 2016).
A surprising but consistent ﬁnding in stem cells studies is that
cardiac retention and engraftment of intravenously administered
MSCs is very low. This has been interpreted as indicating that early
paracrine effects may confer prolonged beneﬁt, perhaps through
phenotype alteration of local macrophages for example. Alterna-
tively, they may mediate systemic anti-inﬂammatory effects. For
example, Luger et al. found that, despite widespread distribution to
tissues aside from the heart, intravenously-administered MSC
treatment after acute MI ameliorated late left ventricular remod-
elling, apparently via systemic anti-inﬂammatory activities (Luger
et al., 2017). Furthermore, if this is the case, it may not be neces-
sary for any MSCs to engraft in the heart at all. In one intriguing
study, MSCs were injected subcutaneously in mice after MI such
that they did not migrate detectably from the injection site, and LV
function was improved (Preda et al., 2014). The protein pentraxin 3
was suggested to be involved in the mechanism of this remote type
of protection (Preda et al., 2014). The potential role of exosomes in
these observations has not yet been investigated.
3. Cardiac stem cell-derived exosomes
MSCs are not the only cell type being investigated in terms of
cardiac cell therapy (Fig. 4). There is great interest in the potential
for various cardiac resident stem cells, including c-kitþ cells, WT1þ
cells and W8B2þ cells to name a few, to restore function to the
injured heart, although there is also a great deal of debate as to
which of these represent bone ﬁde, cardiac-resident stem cells
(Zhang et al., 2015).
Human Sca1þ cardiac progenitor cells (CPCs) harvested from
aborted foetuses have been shown to secrete exosomes into culture
medium (Vrijsen et al., 2010). After puriﬁcation by ultracentrifu-
gation and density gradient, these exosomes can stimulate the
migration of endothelial cells in an in vitro scratch wound assay
(Vrijsen et al., 2010). In these experiments, migration was blocked
by a neutralizing antibody against extracellular matrix metal-
loproteinase inducer (EMMPRIN) (Vrijsen et al., 2010). CPCs can
also be obtained from the right atrial appendages of patients un-
dergoing cardiac surgery. Exosomes puriﬁed from these cultured
are also capable of stimulating endothelial tube formation (Barile
et al., 2014). Furthermore, when injected into the infarct border
zone these CPCs-EVs reduced cardiomyocyte apoptosis and scar,
increased both viable mass in the infarct area and blood vessel
density, and prevented the early impairment of ventricular function
at day 7 in a permanent ligation rat model of acute MI (Barile et al.,
2014). Interestingly, in this study, EVs isolated from dermal ﬁbro-
blasts did not confer any beneﬁt, suggesting the beneﬁts are spe-
ciﬁc to stem cells (Barile et al., 2014). It is not entirely clear whatPlease cite this article in press as: Davidson, S.M., Yellon, D.M., Exosom
Medicine (2017), https://doi.org/10.1016/j.mam.2017.11.004characteristics of stem cells are important in order for them to
produce exosomes that are beneﬁcial to the ischaemic heart.
Indeed, it has previously been suggested that ex vivo cultured ﬁ-
broblasts and MSC are, in fact, indistinguishable by all commonly
used parameters (Hematti, 2012). Both ﬁbroblasts and MSCs are
multipotent. Both have immunosuppressive qualities (Haniffa et al.,
2009). A comparison of the proteome and miRnome of exosomes
from stem cells and ﬁbroblasts may reveal important differences.
An important factor affecting the potency of CPCs may be the
age of the donor. In a study comparing human c-kitþ CPCs from
adults and neonates, those from neonates proliferated more in vitro
and led to greater myocardial recovery in rats when injected
intramyocardially after permanent coronary artery ligation
(Sharma et al., 2017). Interestingly, exosomes produced by the
neonatal CPCs appeared to be responsible for a large proportion of
this beneﬁt, although a non-exosomal fraction also delivered some
beneﬁt (Sharma et al., 2017). Exosomes from hypoxic (but not
normoxic) c-kitþ rat CPCs were found to improve cardiac function
and reduce ﬁbrosis after ischaemia followed by 3 weeks reperfu-
sion (Gray et al., 2015). They were also found to enhanced tube
formation of endothelial cells and decreased proﬁbrotic gene
expression in TGF-b-stimulated ﬁbroblasts in vitro (Gray et al.,
2015). A separate study found that c-kitþ CPC exosomes isolated
from the right atrial appendages of children undergoing cardiac
surgery were not protective when administered intramyocardially
to athymic rats after IR, in comparison to those from neonatal
hearts (Agarwal et al., 2017). Interestingly, hypoxic culture could
restore some of the protective ability of CPCs exosomes (Agarwal
et al., 2017).
When c-kitþ stem cells are isolated from the heart it is impor-
tant to exclude mast cells, which also express c-kitþ, but can be
excluded on the basis of being CD45þ. This step is particularlyes and cardioprotection e A critical analysis, Molecular Aspects of
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et al., 2010). Interestingly, exposure of mouse mast cells to oxida-
tive stress causes an alteration in the mRNA content of exosomes
released (Eldh et al., 2010). Furthermore, these exosomes can in-
ﬂuence the response of other cells to oxidative stress by providing
recipient cells with a resistance against oxidative stress (Eldh et al.,
2010).
Based on the concept that exosomes may mediate part of the
paracrine beneﬁt of transplanted stem cells, MSC exosomes have
been used to “precondition” stem cells before transplantation. In
these experiments, cardiac stem cells (CSCs) were exposed in vitro
to exosomes isolated from cultured rat BM-MSCs using Exoquick-
TCTM (Zhang et al., 2016). This was found to stimulate the prolif-
eration, migration, and angiotube formation of the CSCs (Zhang
et al., 2016). When injected in a rat myocardial infarction model,
the preconditioned CSCs had signiﬁcantly improved survival,
enhanced capillary density, reduced cardiac ﬁbrosis, and restored
long-term cardiac function (Zhang et al., 2016). However, since the
isolated particles measured only 10e80 nm there is a concern that
lipoprotein particles from the serum may have contributed to the
preconditioning effects (Zhang et al., 2016).
Ong et al. used a novel genetic strategy to try to enhance the
healing properties of Sca1þ murine CPCs by targeting the sup-
porting stromal cells. By co-delivering a minicircle plasmid
encoding HIF-1 with the CPCs, the surrounding stromal cells were
made to overexpress HIF-1, which appears to have increased
transfer of miR-126 and miR-210 via exosomes to the recipient
CPCs, activating prosurvival kinases and inducing a glycolytic
switch (Ong et al., 2014).
Recently, a novel population of cardiac resident stem cells were
described, which were obtained from adult human atrial append-
ages and shown to be positive for the W8B2 antigen TNAP (Tissue
non-speciﬁc alkaline phosphatase), that is selectively expressed on
MSCs (Zhang et al., 2015). W8B2þ CPCs express mesenchymal
markers and can differentiate into cardiovascular lineages. The
conditioned medium had prosurvival, proangiogenic, and pro-
migratory effects on endothelial cells, as well as protective cells
on neonatal rat cardiomyocytes. Intramyocardial transplantation of
human W8B2þ CPCs markedly improved cardiac function of rats 1
week after myocardial infarction. It was recently demonstrated that
W8B2þ cells secrete exosomes that may mediate these effects (Nie
et al., 2017).
4. Embryonic stem (ES) cells-derived exosomes
Extrapolating from the advantages described above with using
CPC exosomes from younger donors, it might be hypothesized that
exosomes produces by embryonic stem (ES) cells, which are by
deﬁnition even younger, and which furthermore are totipotent as
opposed to multipotent, might be even more efﬁcacious in pro-
tecting and regenerating the heart. As with studies using other
sources of exosomes, exosomes from mouse ES cells enhanced
neovascularization, cardiomyocyte survival and reduced ﬁbrosis
post infarction (Khan et al., 2015). Interestingly, after 8 weeks, an
increase in c-kitþ CPCs and new cardiomyocytes was observed in
the heart of mice receiving these exosomes (Khan et al., 2015).
Furthermore, it might be speculated that these new CPCs would
contribute their own beneﬁcial exosomes to the healing process in
a kind of “virtuous circle”. Interestingly, miR-294 was found to be
particularly enriched in exosomes from ES cells, and delivery of this
miRNA to CPCs was sufﬁcient to promote their increased survival,
cell cycle progression and proliferation (Khan et al., 2015).
Human ES cell-derived cardiovascular progenitors (hESC-Pg)
have been administered intramyocardially 2e3 weeks after coro-
nary artery occlusion, and were found to enhance recovery ofPlease cite this article in press as: Davidson, S.M., Yellon, D.M., Exosom
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heart (Kervadec et al., 2016). It was hypothesized that EVsmediated
the beneﬁts of transplanted cells, since they were able to recapit-
ulate the effects (Kervadec et al., 2016). Although exosomes were
present in the isolated EVs, the effect could not be reliably assigned
to them, since there were also a large number of MVs present
(Kervadec et al., 2016).
5. Hematopoietic stem cell-derived exosomes
Bone marrow derived CD34þ hematopoietic stem cells have
been investigated as a means of promoting angiogenesis in
ischaemic hearts, thereby preserving cardiac function. Exosomes
puriﬁed from human CD34þ stem cells by ultracentrifugation
through a sucrose gradient cushion were found to increase endo-
thelial cell viability, proliferation, and tube formation (Sahoo et al.,
2011). Interestingly, although exosomes from CD34þ cells stimu-
lated angiogenesis in Matrigel plugs implanted in vivo, those from
the mononuclear cells remaining after depletion of CD34þ cells did
not (Sahoo et al., 2011). CD34þ exosomes were therefore proposed
to mediate the proangiogenic paracrine activity of the parent cells
(Sahoo et al., 2011). Human CD34þ stem cell exosomes were also
found to induce repair of ischaemic hind limb by stimulating
angiogenic mechanisms via a mechanism involving transfer of miR-
126-3p (Mathiyalagan et al., 2017). In these experiments, the
greatest internalization of CD34þ exosomes was observed into
endothelial cells relative to smooth muscle cells and ﬁbroblasts of
ischaemic hindlimbs (Mathiyalagan et al., 2017).
When injected into the ischaemic border zone of immune-
compromised mice after coronary artery ligation, human
CD34þ cells were found not to be protective (Mackie et al., 2012).
However, if they were ﬁrst engineered to overexpress the known
angiogenic factor, sonic hedgehog (Shh), ventricular size and car-
diac function were maintained (Mackie et al., 2012). The modiﬁed
cells were shown to release Shh in exosomes and activate the ca-
nonical Shh signalling pathway in recipient cells. Interestingly,
microvesicles generated from activated/apoptotic human T lym-
phocytes have also been found to contain Shh naturally, and when
administered to mice receiving angiotensin II, they were found to
revert hypertension and endothelial dysfunction through a mech-
anism associated with Shh-induced production of nitric oxide, and
by decreasing levels of oxidative stress (Marrachelli et al., 2013).
6. Exosome from cardiosphere-derived cells
Cardiosphere-derived cells (CDCs) are a unique type of cardiac-
derived stem cell originally identiﬁed in the Marban lab that are
expanded ex vivo from patient cardiac biopsies (Smith et al., 2007).
CDCs exhibit multi-lineage differentiation and have been shown in
various preclinical models to improve cardiac function after de-
livery to ischaemic myocardium (Cheng et al., 2014a; White et al.,
2013). CDCs contain a mix of cell types, including some c-
kitþ cells, but themajority of the “active” cell type are believed to be
CD105þ/CD90/c-kit cells (Cheng et al., 2014b). Of particular in-
terest, a phenomenon coined “cellular postconditioning” has been
identiﬁed whereby CDCs have been shown to protect the hearts of
pigs or hypertensive rats when administered 20e30 min after the
onset of reperfusion. This characteristic of delayed protection is
somewhat of a “holy grail” for cardioprotection, since it implies that
procedures can be implemented after a substantial delay and still
provide signiﬁcant patient beneﬁt. The mechanism of this delayed
protection appears to be due to their effect on polarizing cardiac
macrophages toward a distinctive cardioprotective phenotype (de
Couto et al., 2015; Kanazawa et al., 2015, 2016). However, in this
regard, it is interesting to note that similar beneﬁts have beenes and cardioprotection e A critical analysis, Molecular Aspects of
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presenting phosphatidylserine on their surface, which causes them
to be taken up by macrophages, improving the resolution of
inﬂammation, stimulating angiogenesis and elicit infarct repair
(Harel-Adar et al., 2011).
After a promising, albeit small, phase I trial, the ALLSTAR mul-
ticentre randomized, double-blind, placebo-controlled trial of
allogeneic CDCs in patients with myocardial infarction (MI) and
ischemic left ventricular dysfunction progressed to a larger phase 1/
2 safety and efﬁcacy trial of intracoronary delivery (Chakravarty
et al., 2017). Unfortunately, the trial was recently reported to have
been terminated early due to low probability of attaining its pri-
mary endpoint of a reduction in myocardial scarring due to
infarction (Capricor Therapeutics, 2017). However, given that the
mechanism of action of CDCs in experimental models seems to be
via the release of paracrine factors, there remains great interest in
the potential for CDC exosomes to confer a cardioprotective beneﬁt.
Human CDC exosomes have been administered to pigs in both
acute and chronic models of cardiac ischaemia. Interestingly, they
reduced infarct size and preserved systolic function after intra-
myocardial but not intracoronary delivery (Gallet et al., 2017).
Notably, signiﬁcantly more allo-antibodies were observed in hearts
that had received exosomes, indicative of a mild immune response.
It is also worthwhile to consider that the exosomes used in these
studies were prepared by precipitation with polyethylene glycol
(PEG), which is generally not recommended as the exosomes are
regarded as being relatively impure (Paolini et al., 2016). Further-
more, the effect of the residual PEG on cardiac function is not
known. Interestingly, as had been observed with CDC cells them-
selves, administration of CDC exosomes 20e30 min after reperfu-
sion reduced infarct size in both rat and pig models of MI measured
48 h later (de Couto et al., 2017).
In these studies, the cardioprotective effects were said to derive
from exosomal transfer of miR-181b from CDCs into macrophages
which reduced PKCd transcript levels (de Couto et al., 2017).
Interestingly, although ﬁbroblast exosomes were not protective in
this model, those that had been loaded selectively with miR-181b
were then able to alter macrophage phenotype and deliver car-
dioprotection (de Couto et al., 2017).
Part of the longer-term beneﬁt of CDCs may also be via
reprogramming of resident ﬁbroblasts. When dermal ﬁbroblasts
were primed with exosomes from rat CDCs for 24 h in vitro, they
were rendered therapeutic, and were able to stimulate angiogen-
esis and improve cardiac remodelling when injected intra-
myocardially 1 month after induction of MI in rats (Tseliou et al.,
2015). Interestingly, the primed ﬁbroblasts secreted higher levels
of stromal-cell-derived factor 1 (SDF-1a) and vascular endothelial
growth factor (VEGF) (Tseliou et al., 2015).
Curiously, the acute reduction in infarct size mediated by CDC
exosomes has been attributed to a Y RNA fragment they contain
called EV-YF1, with the potency of CDCs in vivo correlated with the
content of EV-YF1 (Cambier et al., 2017). Y RNAs are small non-
coding RNAs that form components of the Ro60 ribonucleopro-
tein particle involved in DNA replication. Exosomes transfer EV-YF1
from CDCs tomacrophages, resulting in them increasing expression
of the immunosuppressive cytokine Il-10 (Cambier et al., 2017).
CDC exosomes also contain more commonly known small RNAs
including miRNAs, particularly miR-146a, which appears to
mediate part of the regenerative and functional effects of CDC
exosomes injected into mice (Ibrahim et al., 2014).
7. Plasma exosomes
Exosomes and other EVs are present at high concentrations in
blood, and may have a role in communication between organs orPlease cite this article in press as: Davidson, S.M., Yellon, D.M., Exosom
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somes isolated from human or rat blood by differential ultracen-
trifugation have been shown to be cardioprotective, reducing
infarct size when administered intravenously to rats, or added to
isolated, perfused rats hearts or primary cardiomyocytes (Vicencio
et al., 2015). HSP70 present on the surface of plasma exosomes was
shown to stimulate the TLR4 receptor on cardiomyocytes, leading
to activation of the ERK1/2 pathway, which is a central component
of the cardioprotective RISK pathway (Vicencio et al., 2015). Inhi-
bition of any of these steps also blocked cardioprotection (Vicencio
et al., 2015). However, it was recently demonstrated that exosomes
isolated using the same technique from the blood of rats or humans
with type II diabetes were unable to activate ERK1/2 and had lost
this cardioprotective ability (Davidson et al., 2017b). These data
suggest that plasma exosomes might exert a continuous, mild
stimulatory effect of cardioprotective pathways in the heart.
Furthermore, it has been suggested an increase in the number of
activity of plasma exosomes might be responsible for the trans-
mission of a cardioprotective signal from the remotely conditioned
limb to the heart during the process of RIPC (Yellon and Davidson,
2014). Indeed, in both humans and rats, RIPC has been found to
increase the quantity of exosomes in the blood (Vicencio et al.,
2015). However, only a marginal, non-signiﬁcant increase in pro-
tectionwas observed with exosomes isolated after RIPC, suggesting
this is not the only mechanism involved in this phenomenon
(Davidson et al., 2013; Vicencio et al., 2015). On the other hand,
evidence obtained using experiments in which the efﬂuent from
one perfused heart is transferred to a second heart suggests that
exosomes may be able to transmit protection between organs
(Giricz et al., 2014). Probably, the deﬁnitive answer regarding the
requirement for exosomes in RIPC awaits the development of a
speciﬁc inhibitor of in vivo exosomes production, as discussed in
section 8.
It may turn out to be the case that EVs other than exosomes
mediate RIPC, though here the data is similarly contrasting. Jean-
neteau et al. found that RIPC caused an increase in the number of
circulating endothelial MVs and procoagulant MVs in rats and
humans, but infarct size was not altered by intravenous injection of
MVs from an RIPC-treated rat (Jeanneteau et al., 2012). However,
Ma et al. found that MV injection reduced infarct size (Ma et al.,
2015), perhaps because they combined the MVs isolated from 3
rats to inject into each rat, leading to a greater overall increase in EV
number (Ma et al., 2015).
8. Perspectives
Despite the numerous promising studies the have observed
impressive cardioprotective beneﬁts with exosomes administered
to hearts, either after acute IR, or in a chronic model of permanent
ischaemia, the results must be interpreted with caution. Many
studies used relatively impure populations of vesicles. Some pre-
cipitation methods of puriﬁcation such as Exoquick can result in
relatively low purity (Sluijter et al., 2017; Paolini et al., 2016). Un-
fortunately, a practical method of isolating high yields of very pure
exosomes remains to be developed. Lipoprotein particles and/or
proteins remain a major potential contaminant from serum-
containing medium using any commonly used technique
including differential centrifugation, precipitation, and size-
exclusion chromatography (Sodar et al., 2016; Yuana et al., 2014).
In the meantime, the most pragmatic option seems to be to isolate
exosomes from cells cultures for 1e2 days in serum-free medium,
although it is essential to verify that the cells have not started to
undergo apoptosis. In any case, this period of serum starvation is
known to dramatically alter the metabolism of cultured cells, and
the exosomes that are produced under this condition may be quitees and cardioprotection e A critical analysis, Molecular Aspects of
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Several techniques are commonly used to verify the presence of
exosomes in an isolate, but all are subject to limitations. TEM is
highly selective and in any case, many (if not most) ﬁgures of
“exosomes” presented in papers bear little resemblance to the
classical “cup-shaped” vesicle expected when the exosomes
collapse during drying in preparation for TEM (Thery et al., 2006).
NTA can estimate size distribution and concentration of particles,
but cannot distinguish between exosomes, lipoprotein particles,
protein aggregates, or other similarly sized particles such as cal-
cium precipitates. Western blotting can demonstrate the presence
of exosome “marker proteins” such as Alix, HSP70, CD63, CD81 and
CD9, but by itself is not a good indication of purity, although the
demonstration of the absence of other membrane proteins such as
ER and plasma membrane can help in this regard. Furthermore,
some of the aforementioned marker proteins (particularly CD63)
seem to be expressed on other small EVs including MVs and so are
not very discriminatory for exosomes (Kowal et al., 2016). For all of
these reasons, the development of more robust techniques to
isolate exosomes and to validate their purity is essential to avoid
them becoming the new “snake oil” e able to cure anything, but
without anyone really knowing what is in them.
Many experiments demonstrating functional effects with exo-
somes have been performed in vitro using cultured cells (Fig. 4), and
although these experiments are informative, the extent to which
the effects reﬂect real in vivo processes is not entirely clear. Cleverly
designed experiments will be needed, such as those using in vivo
transfer of Cre mRNA to demonstrate that EVs can transfer meta-
static behaviour from cancer cells to benign cells (Zomer et al.,
2015b).
Reliable tracing of exosomes remains challenging, particularly
in vivo. Fluorescent lipophilic dyes are sometimes used for this
purpose, but can be misleading since they incorporate avidly into
lipoprotein particles (present in serum used for cell culture), and
even bind efﬁciently to protein components of the medium that are
unavoidable for the culture of healthy cells (Takov et al., 2017).
Thus, it is difﬁcult to interpret experiments using these dyes.
Another approach is to radiolabel vesicles. In several studies,
intravenously administered exosomes have been observed to
accumulate in lung and liver. However, given some of the limita-
tions and caveats discussed above concerning the purity of exo-
some preparations, it is difﬁcult to be conﬁdent that this is not due
to impurities. A more robust assay has been developed which in-
volves expression of luciferase and noninvasive bioluminescence
imaging (Lai et al., 2014). Using this method, labelled B16-BL6
exosomes were observed to disappear very quickly from the blood
circulation with a half-life of only ~2 min (Takahashi et al., 2013).
However, most luminescence was still observed in the liver and
lungs. Therefore, it seems that intramyocardial injection may be
necessary to achieve sufﬁcient delivery of exosomes to the heart. In
this regard, a recent study demonstrated that CDC exosomes were
effective in pigs after intramyocardial but not intracoronary de-
livery post reperfusion (Gallet et al., 2017). Ultimately, new
methods must be developed to improve targeted delivery to the
heart of exosomes delivered intravenously.
One important consideration is that, despite reproducible ben-
eﬁts of stem cell administration in animal experiments, substantial
debate remains as to whether stem cell implantation provides any
beneﬁt at all to patients with ischaemic heart disease (Gyongyosi
et al., 2016). While it seems certain that cell engraftment is rare,
and cardiac regeneration even rarer, the hypothesis that they pro-
vide a signiﬁcant beneﬁt to cardiovascular function via a paracrine
effect is not well substantiated by current clinical data. In this case,
it is conceptually challenging to understand how the puriﬁed
paracrine factor (i.e.: exosomes) can be expected to be any morePlease cite this article in press as: Davidson, S.M., Yellon, D.M., Exosom
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likely, is that the exosomes produced by in vitro cultured cells have
different characteristics to those produced by cells in vivo. It may
therefore be possible to use stem cells as an artiﬁcial bio-reactor
producing beneﬁcial exosomes ex vivo. The ﬁrst experiments
administering exosomes in vivo have begun, although the regula-
tions regulating this new biologic remain relatively poorly deﬁned
(Lener et al., 2015). One attractive aspect of exosomes is that they
may potentially be able to confer some of the beneﬁts of stem cells,
without the limitation such as the risk of teratomas developing
from transplanted stem cells (Madonna et al., 2016).
Ideally, to prove that exosomesmediate an effect, onewould use
chemical or genetic suppression of exosome production to inves-
tigate whether they also suppress the effect. Unfortunately, current
inhibitors such as GW4869 are fairly non-speciﬁc, and though Rab
proteins are generally thought to be involved in exosome produc-
tion, the precise member of this large family appears to vary be-
tween cell types (Colombo et al., 2014). In the meantime, one must
rely on experiments such as those demonstrating that an affect is
absent in conditioned medium depleted of exosomes. The majority
of functional experiments to date have been performed using cells
in culture, and their signiﬁcance in vivo is difﬁcult to ascertain.
Emerging evidence suggests that there are multiple subtypes of
small EVs, which may have different characteristics. For instance, it
was recently shown that immature and mature dendritic cells
release EVs that differ in their capacity to orient T helper (Th) cell
responses (Tkach et al., 2017). By afﬁnity isolation of EVs with
different contents of cell membrane lipids, MSCs were shown to
release at least three different subtypes of EVs, although it is not
known if they exhibit different functionalities (Lai et al., 2016). This
fact renders it important ﬁrstly to ensure isolations of exosomes are
as pure as possible, and secondly to investigate possible diverse
effects of difference subtypes of EVs or exosomes.
It is also important to be aware that factors inﬂuencing the
differentiation status of stem cells are likely to inﬂuence the func-
tionality of exosomes that are produced. In particular, examples
given in the sections above illustrate how the microenvironment or
disease conditions such as inﬂammation, diabetes (hyper-
glycaemia) and hypoxia can dramatically alter the contents, pack-
aging and functionality of exosomes derived from phenotypically
similar stem cells.
In summary, given the uncertainties regarding the purity of
exosome isolates, it is difﬁcult to be certain which of the many
qualities attributed to exosomes (Fig. 3) is indeed mediated by
them, and which are artefacts due to isolation procedures or con-
taminants. To this end, in order to improve the quality of the data
and establish with conﬁdence the potential for exosomes to protect
the heart, it is very important to adhere to some of the recently
published consensus recommendations on exosome methods
(Sluijter et al., 2017; Lener et al., 2015; van der Pol et al., 2016;
Witwer et al., 2013; Coumans et al., 2017).
However, several important conclusions can be drawn fromdata
published to date. These include the observation that exosomes
work across species, from human to mice and pigs, suggesting a
highly conserved mechanism. Furthermore, the beneﬁcial effect of
exosomes seems to universally present in exosomes isolated from
stem cells of different origin, as well as those from plasma. On the
other hand, exosomes from ﬁbroblasts are generally found to be
inert. The mechanism of protection is difﬁcult to ascertain, and the
results of miRNA studies in particular are not highly consistent.
However, generally although exosomes appear to have immuno-
suppressive effects there have been some reports of a minor im-
mune response after injection (Gallet et al., 2017). Given their long
duration of action, the hypothesis that exosomes alter or reprogram
endogenous cells of the immune system for example, is attractive.es and cardioprotection e A critical analysis, Molecular Aspects of
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thought of as nothing more than cellular debris, there remains a
great deal to be discovered about these enigmatic vesicles.
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